MIRM Q1 2024 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$69M+119.1% YoY

Gross Profit

$51M74.2% margin

Operating Income

-$26M-38.2% margin

Net Income

-$25M-36.5% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

-0.5%

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

$15M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$652M

Total Liabilities

$417M

Stockholders' Equity

$235M

Cash & Equivalents

$303M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$32M	+119.1%
Gross Profit	$51M	$27M	+93.1%
Operating Income	-$26M	-$27M	+2.5%
Net Income	-$25M	-$30M	+16.1%

Revenue Segments

Product

$69M100%

License and Other Revenue

$305,0000%

Geographic Segments

UNITED STATES

$56M81%

Rest Of World

$13M19%